Table 2

Observed radiographic changes from baseline to week 104

Between-group differences in net % patients with progression,
Etanercept—Control (95% CI)
EndpointCohortImproved n/N (%)Worsened n/N (%)Net % patients with progression,*† unadjusted
(95% CI)
Unadjusted analysisAdjusted analysis
∆ in mNY criteriaControl
Etanercept
3/193 (1.6)
4/162 (2.5)
6/193 (3.1)
1/162 (0.6)
1.6% (−1.3 to 4.4)
−1.9% (−4.9 to 1.2)
−3.4% (−7.6 to 0.8)
p=0.11
−4.7% (−9.9 to 0.5)
p=0.07
∆ ≥1 grade in ≥1 SIJControl
Etanercept
21/193 (10.9)
19/162 (11.7)
36/193 (18.7)
16/162 (9.9)
7.8% (0.6 to 15.0)
−1.9% (−9.7 to 6.0)
−9.6%
(−20.3 to 1.0)
p=0.08
−18.2%
(−30.9 to −5.6)
p=0.005
∆ ≥1 grade in ≥1 SIJ; shift from 0 to 1 or 1 to 0 considered no ΔControl
Etanercept
16/193 (8.3)
15/162 (9.3)
29/193 (15.0)
14/162 (8.6)
6.7% (0.3 to 13.2)
−0.6% (−7.6 to 6.4)
−7.4%
(−16.9 to 2.2)
p=0.13
−16.4%
(−27.9 to −5.0)
p=0.005
  • Based on two of three readers assigning same category; otherwise considered no change.

  • Some patients started with lowest possible score and could not improve.

  • *Net % patients with progression=number of patients with worsening minus the number of patients with improvement, divided by the study population.

  • †One-way analysis of variance.

  • Adjusted for these covariates at baseline: sex, symptom duration, smoking status, human leucocyte antigen-B27 status, Ankylosing Spondylitis Disease Activity Score, Spondyloarthritis Research Consortium of Canada MRI SIJ score and SIJ mNY grade.

  • ∆, change; mNY, modified New York; SIJ, sacroiliac joint.